Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser vs. old laser: which is better for fixing nearsightedness?

NCT ID NCT07505264

Symptom relief Sponsor: Singapore Eye Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two laser platforms used in SMILE surgery to correct short-sightedness (myopia). The standard VISUMAX 500 will be tested against the newer VISUMAX 800 in 100 participants. Researchers want to see if the newer platform provides the same or better vision results and a more comfortable experience.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SMILE surgery (laser procedure)
What this could lead to
If the newer VISUMAX 800 platform works as well or better, it could offer a faster or more comfortable option for laser eye surgery to correct short-sightedness.
What could go wrong
This is a small, early-stage comparison study with only 100 participants. The newer platform may not show meaningful improvement over the existing one, and individual results vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cycloplegic spherical equivalent of \>-1.00D * Refractive cylinder -2.00 D or less; anisometropia \<1.00D * Best spectacle corrected visual acuity (BSCVA) of 6/12 or better in both eyes * Spherical or cylindrical error has progressed at -0.50 D or less per year from date of baseline measurement in both eyes * Contact lens wearers must have removed contact lenses at least 2 weeks before the baseline measurement * No evidence of irregular astigmatism on corneal topography in both eyes Exclusion Criteria: * Progressive or unstable myopia and/or astigmatism * Clinical or corneal topographic evidence of keratoconus * Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract, and retinal disease * Previous corneal surgery or trauma within the corneal flap zone * Patent corneal vascularization within 1 mm of the corneal flap zone * Taking systemic medications likely to affect wound healing, such as corticosteroids and antimetabolites * Systemically immunocompromised or systemic disease likely to affect wound healing, such as diabetes, connective tissue disease, and severe atopy; pregnant or nursing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Singapore National Eye Centre (SNEC)

    RECRUITING

    Singapore, 169856, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.